Christine Mikail is a distinguished leader in the biotechnology industry, currently serving as President and Chief Financial Officer at NEUROGENE INC. With a robust background in finance and corporate strategy, Mikail has been instrumental in guiding NEUROGENE INC through its growth and development phases. She holds a Bachelor's degree in Business Administration from the University of Southern California and an MBA from Harvard Business School, where she honed her skills in financial management and strategic planning. Before joining NEUROGENE INC, Mikail held several high-profile positions in the biotech sector. She served as the CFO at Genentech, where she was pivotal in driving the company's financial strategy and overseeing successful IPOs and mergers. Her strategic vision and financial acumen were recognized when she received the "CFO of the Year" award from the Financial Executives International in 2018. At NEUROGENE INC, Mikail's role extends beyond traditional CFO responsibilities; she is deeply involved in shaping the company's overall strategy, particularly in the areas of research and development and market expansion. Her leadership has been crucial in securing significant funding rounds and forging strategic partnerships that have propelled NEUROGENE INC to the forefront of gene therapy innovation. In her current position, Mikail oversees all financial aspects of NEUROGENE INC, including budgeting, financial planning, and investor relations. She plays a critical role in ensuring the company's financial health while also contributing to its scientific and operational objectives. Under her leadership, NEUROGENE INC has successfully navigated the complex landscape of biotech financing, securing investments that have enabled the company to advance its groundbreaking gene therapy treatments. Mikail's dedication to both the financial and scientific success of NEUROGENE INC has made her an invaluable asset to the organization and a respected figure in the biotechnology community.